

Kian-Huat Lim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3720030/publications.pdf>

Version: 2024-02-01

67
papers

5,668
citations

201674

27
h-index

118850

62
g-index

68
all docs

68
docs citations

68
times ranked

9749
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogenically active MYD88 mutations in human lymphoma. <i>Nature</i> , 2011, 470, 115-119.	27.8	1,292
2	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 651-662.	10.7	557
3	Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. <i>Genes and Development</i> , 2007, 21, 1714-1719.	5.9	346
4	Activation of RalA is critical for Ras-induced tumorigenesis of human cells. <i>Cancer Cell</i> , 2005, 7, 533-545.	16.8	330
5	RALA and RALBP1 regulate mitochondrial fission at mitosis. <i>Nature Cell Biology</i> , 2011, 13, 1108-1115.	10.3	327
6	Toll-Like Receptor Signaling. <i>Cold Spring Harbor Perspectives in Biology</i> , 2013, 5, a011247-a011247.	5.5	306
7	Tumour maintenance is mediated by eNOS. <i>Nature</i> , 2008, 452, 646-649.	27.8	289
8	The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis. <i>Cancer Research</i> , 2008, 68, 7561-7569.	0.9	234
9	Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells. <i>Current Biology</i> , 2006, 16, 2385-2394.	3.9	212
10	Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. <i>Cancer Cell</i> , 2005, 8, 381-392.	16.8	168
11	Tumor Stroma IL1 β -IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer. <i>Cancer Research</i> , 2018, 78, 1700-1712.	0.9	134
12	Pathogenetic importance and therapeutic implications of NF κ B in lymphoid malignancies. <i>Immunological Reviews</i> , 2012, 246, 359-378.	6.0	129
13	Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 68-84.	3.2	123
14	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2020, 6, 60.	7.1	112
15	Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA. <i>Molecular and Cellular Biology</i> , 2010, 30, 508-523.	2.3	100
16	Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. <i>Gut</i> , 2020, 69, 122-132.	12.1	89
17	Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 249.	17.1	88
18	Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?. <i>Oncologist</i> , 2012, 17, 192-200.	3.7	83

#	ARTICLE	IF	CITATIONS
19	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. <i>Nature Communications</i> , 2021, 12, 5086.	12.8	58
20	Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 1748-1759.	7.0	56
21	Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. <i>Hpb</i> , 2017, 19, 133-139.	0.3	54
22	Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. <i>Clinical Cancer Research</i> , 2019, 25, 6107-6118.	7.0	54
23	The clonal evolution of metastatic colorectal cancer. <i>Science Advances</i> , 2020, 6, eaay9691.	10.3	41
24	Immunotherapy in gastrointestinal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 474-484.	1.4	36
25	Sec5 and Exo84 Foster Oncogenic Ras-Mediated Tumorigenesis. <i>Molecular Cancer Research</i> , 2010, 8, 223-231.	3.4	34
26	Current biologics for treatment of biliary tract cancers. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 430-440.	1.4	33
27	Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2144-2155.	4.1	32
28	CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. <i>ACS Nano</i> , 2021, 15, 1186-1198.	14.6	32
29	IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer. <i>JCI Insight</i> , 2019, 4, .	5.0	26
30	Use of Retrovirus Expression of Interfering RNA to Determine the Contribution of Activated Kâ€Ras and Ras Effector Expression to Human Tumor Cell Growth. <i>Methods in Enzymology</i> , 2006, 407, 556-574.	1.0	21
31	Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial. <i>Clinical Colorectal Cancer</i> , 2021, 20, e185-e193.	2.3	20
32	TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations. <i>Journal of Clinical Investigation</i> , 2020, 130, 4771-4790.	8.2	20
33	Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 379-386.	1.4	19
34	IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology</i> , 2022, 162, 2047-2062.	1.3	18
35	Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. <i>World Journal of Gastroenterology</i> , 2021, 27, 2105-2121.	3.3	17
36	Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression. <i>Hepatology Communications</i> , 2018, 2, 148-151.	4.3	16

#	ARTICLE	IF	CITATIONS
37	Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 985-989.	1.4	14
38	Folate Receptor $\hat{\pm}$ -Targeted ^{89}Zr -M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer. <i>Molecular Pharmaceutics</i> , 2019, 16, 3996-4006.	4.6	12
39	Deciphering the Role of Innate Immune NF- $\hat{\kappa}$ B Pathway in Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 2675.	3.7	12
40	FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers. <i>JAMA Oncology</i> , 2020, 6, 1231.	7.1	12
41	IRAK4 Kinase As A Novel Therapeutic Target in the ABC Subtype of Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2012, 120, 62-62.	1.4	12
42	Phase IB study of FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 338-338.	1.6	11
43	Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities. <i>Cancers</i> , 2021, 13, 5481.	3.7	11
44	Evolving Paradigms in the Systemic Treatment of Advanced Gallbladder Cancer: Updates in Year 2022. <i>Cancers</i> , 2022, 14, 1249.	3.7	9
45	A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 24250-24261.	1.8	8
46	Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2199-2204.	2.0	7
47	Combined Systemic and Hepatic Artery Infusion Pump Chemo-Therapy as a Liver-Directed Therapy for Colorectal Liver Metastasis-Review of Literature and Case Discussion. <i>Cancers</i> , 2021, 13, 1283.	3.7	7
48	Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies. <i>European Journal of Cancer</i> , 2021, 154, 102-110.	2.8	6
49	A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 410-410.	1.6	6
50	Leveling the Playing Field. <i>Molecular Cell</i> , 2004, 15, 491-492.	9.7	5
51	Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 61-67.	1.4	5
52	The MK2/Hsp27 axis is a major survival mechanism for pancreatic ductal adenocarcinoma under genotoxic stress. <i>Science Translational Medicine</i> , 2021, 13, eabb5445.	12.4	5
53	Phase II/III study of SM-88 in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 437-437.	1.6	4
54	A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma. <i>Oncologist</i> , 2021, 26, 722-726.	3.7	3

#	ARTICLE	IF	CITATIONS
55	CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusionsâ€”A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).. Journal of Clinical Oncology, 2021, 39, TPS449-TPS449.	1.6	2
56	FOLFIRINOX as first-line therapy in patients with metastatic gastroesophageal cancers (GEC).. Journal of Clinical Oncology, 2015, 33, 177-177.	1.6	2
57	Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer.. Journal of Clinical Oncology, 2017, 35, TPS505-TPS505.	1.6	2
58	Phospho-Ser784-VCP Drives Resistance of Pancreatic Ductal Adenocarcinoma to Genotoxic Chemotherapies and Predicts the Chemo-Sensitizing Effect of VCP Inhibitor. Cancers, 2021, 13, 5076.	3.7	2
59	A pilot study of liposomal irinotecan plus 5-FU/ LV combined with paricalcitol in patients with advanced pancreatic cancer which progressed on gemcitabine-based therapy.. Journal of Clinical Oncology, 2022, 40, 566-566.	1.6	2
60	Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 763-763.	1.6	1
61	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, TPS4150-TPS4150.	1.6	1
62	Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.. Journal of Clinical Oncology, 2014, 32, TPS2644-TPS2644.	1.6	0
63	Analysis of the effect of adjuvant therapy on overall survival for resected gallbladder adenocarcinoma using the National Cancer Database.. Journal of Clinical Oncology, 2017, 35, 360-360.	1.6	0
64	Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.. Journal of Clinical Oncology, 2017, 35, 2553-2553.	1.6	0
65	Entering the molecular era of gastrointestinal oncology: current updates and challenges. Journal of Gastrointestinal Oncology, 2017, 8, 377-378.	1.4	0
66	Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers.. Journal of Clinical Oncology, 2020, 38, 4532-4532.	1.6	0
67	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial.. Journal of Clinical Oncology, 2022, 40, 284-284.	1.6	0